CD95/Fas stoichiometry in future precision medicine

被引:0
|
作者
Sica, Mauricio [1 ]
Roussel, Murielle [2 ,3 ]
Legembre, Patrick [2 ]
机构
[1] Inst Balseiro UNCuyo, Bariloche Atom Ctr, CONICET, Dept Fis Med GAANS CNEA, Ave Bustillo 9500, San Carlos De Bariloche, Rio Negro, Argentina
[2] Univ Limoges, UMR CNRS 7276, INSERM U1262, CRIBL, 2 Rue Marcland, Limoges, France
[3] CHU Dupuytren, Clin Hematol & Cellular Therapy Dept, Limoges, France
关键词
OSTEOCLAST DIFFERENTIATION FACTOR; FAS LIGAND; SIGNALING PATHWAY; DECOY RECEPTOR; DEATH DOMAIN; TNF; COMPLEX; CELLS; OSTEOPROTEGERIN; IDENTIFICATION;
D O I
10.1038/s41418-025-01493-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD95, also known as Fas, belongs to the tumor necrosis factor (TNF) receptor superfamily. The main biological function of this receptor is to orchestrate and control the immune response since mutations in CD95 or deregulation of its downstream signaling pathways lead to auto-immunity and inflammation. Interestingly, more than twenty years ago, pioneer studies highlighted that like TNFR1, TRAILR1 or CD40, CD95 pre-associates at the plasma membrane in a ligand-independent fashion. This self-association occurs through a domain designated pre-ligand assembly domain or PLAD. Although the disruption of this pre-association prevents CD95 signaling, no drugs targeting this region have been generated because many questions remain on the stoichiometry and conformation of this receptor. Despite more than 40.000 publications, no crystal structure of CD95 alone or in combination with its ligand, CD95L, exists. Based on other TNFR members, we herein discuss the predicted conformation of CD95 at the plasma membrane and how these putative structures might account for the induction of the cell signaling pathways.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways
    Haymour, Layla
    Jean, Mickael
    Smulski, Cristian
    Legembre, Patrick
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (06):
  • [2] CD95/Fas ligand induced toxicity
    Haluck-Kangas, Ashley
    Peter, Marcus E.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2023, 51 (01) : 21 - 29
  • [3] CD95/Fas and metastatic disease: What does not kill you makes you stronger
    Guegan, Jean Philippe
    Ginestier, Christophe
    Charafe-Jauffret, Emmanuelle
    Ducret, Thomas
    Quignard, Jean-Francois
    Vacher, Pierre
    Legembre, Patrick
    SEMINARS IN CANCER BIOLOGY, 2020, 60 : 121 - 131
  • [4] The CD95(APO-1/Fas) DISC and beyond
    Peter, ME
    Krammer, PH
    CELL DEATH AND DIFFERENTIATION, 2003, 10 (01) : 26 - 35
  • [5] Fas receptor (CD95)-mediated apoptosis in leukemic cells
    Komada, Y
    Sakurai, M
    LEUKEMIA & LYMPHOMA, 1997, 25 (1-2) : 9 - 21
  • [6] The CD95(APO-1/Fas) DISC and beyond
    M E Peter
    P H Krammer
    Cell Death & Differentiation, 2003, 10 : 26 - 35
  • [7] URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE PROTECTS AGAINST CD95/FAS-INDUCED FULMINANT HEPATITIS
    Utaipan, Tanyarath
    Otto, Ann-Christin
    Gan-Schreier, Hongying
    Chunglok, Warangkana
    Pathil, Anita
    Stremmel, Wolfgang
    Chamulitrat, Walee
    SHOCK, 2017, 48 (02): : 251 - 259
  • [8] Death the Fas way: regulation and pathophysiology of CD95 and its ligand
    Sharma, K
    Wang, RX
    Zhang, LY
    Yin, DL
    Luo, XY
    Solomon, JC
    Jiang, RF
    Markos, K
    Davidson, W
    Scott, DW
    Shi, YF
    PHARMACOLOGY & THERAPEUTICS, 2000, 88 (03) : 333 - 347
  • [9] CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases
    Le Gallo, Matthieu
    Poissonnier, Amanda
    Blanco, Patrick
    Legembre, Patrick
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [10] CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism
    Guegan, Jean-Philippe
    Pollet, Justine
    Ginestier, Christophe
    Charafe-Jauffret, Emmanuelle
    Peter, Marcus E.
    Legembre, Patrick
    ISCIENCE, 2021, 24 (12)